Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13257175 | 0.93 | LMNA (0.61) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 | |
| Hydrochloric Acid SCHEMBL31198045 | 0.85 | MEN1 (0.58) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 | |
| Hydrochloric Acid SCHEMBL31198000 | 0.84 | RAB9A (0.53) | LMNAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL31197976 | 0.84 | RAB9A (0.53) | LMNAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL31198023 | 0.84 | RAB9A (0.53) | LMNAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL31197989 | 0.82 | RAB9A (0.54) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 | |
| Hydrochloric Acid SCHEMBL31198081 | 0.82 | RAB9A (0.54) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 | |
| Hydrochloric Acid SCHEMBL31197969 | 0.82 | RAB9A (0.54) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 | |
| SCHEMBL9892816 | 0.82 | MEN1 (0.56) | ALDH1A1RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL14758306 | 0.81 | KDM4E (0.70) | LMNAALDH1A1SMN1; SMN2RAB9AELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LMNA 4544/4885ALDH1A1 1724/4885SMN1; SMN2 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.